 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
Sigma-2-Erastin inhibits PC tumor growth through lipid ROS-DUSP6-MAPK signaling (Section 28) - Mar 5, 2024 - Abstract #AACR2024AACR_5474;
ACXT-3102, an orally administered conjugate of sigma-2 ligand and Erastin induces PCD of human PC by uniquely regulating apoptosis and ferroptosis together. Therefore, ACXT-3102 offers a novel and improved therapeutic strategy for treating patients of fatal human carcinomas, especially those, which are difficult to diagnose at an early stage.
- |||| ACXT-3102 / Accuronix Therap
Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 @bvantine1 https://t.co/e48Pu6ozfF (Twitter) - Mar 22, 2023
- |||| ACXT-3102 / Accuronix Therap
P1 data: What's the current state of ACXT-3102 for Synovial Sarcoma? Is a phase 1 trial still in the works? In general - what steps and requirements are taken to start a trial once preclinical rationale for a drug is established, and how long does that process typically take? (Twitter) - Nov 13, 2022
- | ACXT-3102 / Accuronix Therap
Journal: Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT3102. (Pubmed Central) - Aug 18, 2022
Therefore, ACXT-3102 offers a novel and improved therapeutic strategy for treating patients of fatal human carcinomas, especially those, which are difficult to diagnose at an early stage. These findings demonstrate the translational potential of targeting redox homeostasis in ME1 null cancers, and establish the preclinical rational for a phase 1 trial of ACXT-3102 in synovial sarcoma patients.
- |||| ACXT-3102 / Accuronix Therap
Commentary on 👉Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 @bvantine1 https://t.co/Yx6JuKKCfG (Twitter) - Jul 10, 2022
- |||| ACXT-3102 / Accuronix Therap
Based on the article Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 @bvantine1 https://t.co/1g9MmIchpe (Twitter) - Jul 3, 2022
- |||| ACXT-3102 / Accuronix Therap
This is a commentary on @bvantine1 phenomenal work on 👉🏼Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 https://t.co/nCZ40XsJMx (Twitter) - Jun 23, 2022
- |||| ACXT-3102 / Accuronix Therap
Are you ready for ME? Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102 @bvantine1 #AACRsarcoma22 https://t.co/hVu0lHt8O4 (Twitter) - May 12, 2022
- |||| ACXT-3102 / Accuronix Therap
Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT3102 https://t.co/kcYiRklyDv ME is Malic Enzyme 1 #sarcoma #synovialsarcoma (Twitter) - Apr 18, 2022
- Arranon (nelarabine) / Novartis, motixafortide (BL-8040) / BioLineRx
[VIRTUAL] Combined Inhibition of CXCR4 Signaling and System xc- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis (Channel 13 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4485;
P2a
Collectively, these data suggest that T-ALL cells are sensitive to perturbations of the glutathione axis. Combined inhibition of CXCR4 signaling and system xc- activity exploits this vulnerability and presents a promising new therapeutic approach for T-ALL.